Oral Nutritional Supplement in Reducing Surgical Site Infections
NCT ID: NCT02475525
Last Updated: 2018-05-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
6 participants
INTERVENTIONAL
2015-06-30
2017-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protein Supplements in Association With Prehabilitation Program for Cancer Patients Before Surgery
NCT04812704
Impact of Various Diets on Surgical Complications
NCT05069402
The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies
NCT01552291
Outpatient Preoperative Parenteral Nutrition in Malnourished Surgical Patients
NCT03926949
The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery
NCT00559520
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A systematic review in 2011 concluded that arginine supplemented diets among perioperative patients were associated with a reduced rate of surgical infection and reduced overall length of hospital stay.
The study aims are to determine if taking an oral nutritional supplement reduces the rate of wound complications post lower limb revascularization.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arginine enriched oral nutritional supplement group
Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
Arginine enriched oral nutritional supplement
oral nutritional supplement containing arginine
Control
This group will continue on their normal diet before and after surgery. Normal diet will be suspended during their fasting period prior to surgery and will re commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Arginine enriched oral nutritional supplement
oral nutritional supplement containing arginine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients aged \>18 years.
Exclusion Criteria
* emergency cases,
* seriously ill patients/unconscious patients,
* chronic renal disease,
* known inflammatory bowel disease,
* known lactose intolerance and not using lactase,
* known galactosemia,
* pregnancy,
* cows milk allergy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UL Hospitals, Limerick
UNKNOWN
University of Limerick
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mary Clarke Moloney
Clinical Operations Manager
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mary Clarke Moloney
Role: PRINCIPAL_INVESTIGATOR
University of Limerick
Paul Burke
Role: PRINCIPAL_INVESTIGATOR
UL Hospitals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Limerick
Limerick, , Ireland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONS2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.